Shalini Sharp

Chief Financial Officer and Executive Vice President

Ms. Sharp joined Ultragenyx in May 2012 as Chief Financial Officer. She is responsible for leading the corporate finance, strategy, and information technology functions and is a member of the company’s executive leadership team. Ms. Sharp brings to us nearly twenty years of experience in the life sciences industry.

Ms. Sharp is a member of the Board of Directors of Agenus Inc. (formerly Antigenics Inc.), a publicly traded biotechnology firm, where she served as Chief Financial Officer from 2006 to 2012. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development. She is also a member of the Board of Directors of the TB Alliance, a non-profit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world. Prior to Agenus, Ms. Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that company's restructuring. She has spearheaded numerous financing and business development transactions that were critical to the success of Agenus and Elan. Ms. Sharp was also a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices.

Ms. Sharp holds both a B.A., magna cum laude, and M.B.A., from Harvard University.